Company details

Neovacs

  • Print
  • Share Share
en fr

Neovacs specializes in developing active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases.At the end of 2011, the group had a portfolio of 3 products, including 1 in preclinical development phase (VEGF-K; treatment of cancer and age-related macular degeneration) and 2 in clinical development phase (TNFá-K, for treating Crohn's disease and rheumatoid polyarthritis, and IFNá-K, for treating lupus).